University of Michigan
umich.eduTotal trials
1,783
Active
297
Phase 3
46
Total enrollment
620,792
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 84 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Acetaminophen | — | — | — | — | — | 3 | |
| NSAID | — | — | — | — | — | 2 | |
| Opioid | — | — | — | — | — | 2 | |
| Paclitaxel | — | — | — | 13 | |||
| Dupilumab | — | — | — | — | — | 3 | |
| Ibuprofen | — | — | — | — | — | 2 | |
| Warfarin | — | — | — | — | — | 2 | |
| Imiquimod 5% Topical Cream | — | — | — | — | — | 1 | |
| cephalexin | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Vitamin K | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 | |
| Metoprolol Succinate | — | — | — | — | 2 | ||
| Relugolix CT | — | — | — | — | — | 1 | |
| Lexapro | — | — | — | — | — | 1 | |
| Cyclobenzaprine | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 9 | ||
| Mycophenolate Mofetil | — | — | — | 4 | |||
| Temozolomide | — | — | — | — | 3 | ||
| Olaparib | — | — | — | — | — | 3 | |
| Leuprolide | — | — | — | — | — | 2 | |
| Cyclophosphamide | — | — | — | — | — | 2 | |
| Prednisone | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 17 | ||
| Sirolimus | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | 11 | ||
| Ipilimumab | — | — | — | — | 5 | ||
| Tacrolimus | — | — | — | — | — | 5 | |
| Bortezomib | — | — | — | — | 4 | ||
| Ruxolitinib | — | — | — | — | 4 | ||
| Lenalidomide | — | — | — | — | — | 3 | |
| Vorinostat | — | — | — | — | 3 | ||
| Methotrexate | — | — | — | — | — | 3 | |
| Pacritinib | — | — | — | — | 3 | ||
| Enzalutamide | — | — | — | — | 2 | ||
| Caffeine Citrate | — | — | — | — | 2 | ||
| Dextrose Water | — | — | — | — | 2 | ||
| ESK981 | — | — | — | — | — | 2 | |
| Freeze-Dried California Table Grape | — | — | — | — | — | 1 | |
| Starch, Potato | — | — | — | — | — | 1 |
44 more active programs hidden
Next readouts
- 2023-01-26
- 2024-04-08
- 2024-05-02
- 2025-01-06
- 2025-01-08
- 2025-07-30
- 2026-02-21
- 2026-04-16
- 2026-05
- 2026-05-06
Top conditions
- Depression52
- Breast Cancer50
- Healthy38
- Prostate Cancer38
- Obesity28
- Hypertension23
- Anxiety21
- Chronic Pain19
Frequently asked questions about University of Michigan
- How many clinical trials does University of Michigan have on ClinicalTrials.gov?
- University of Michigan is listed as the lead sponsor on 1,783 clinical trials in ClinicalTrials.gov, 297 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Michigan's trials are in Phase 3?
- 46 of University of Michigan's trials are in Phase 3, spread across 84 active drug programs.
- What therapeutic areas does University of Michigan focus on?
- University of Michigan's most-studied conditions on ClinicalTrials.gov are Depression, Breast Cancer, Healthy, Prostate Cancer, Obesity.
- When are University of Michigan's next clinical trial readouts?
- University of Michigan has 10 upcoming primary-completion readouts tracked here; the soonest is “Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)”, expected around 2023-01-26.